NCT04050462终止2 期
A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 in Advanced Hepatocellular Carcinoma (HCC) Patients
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 13
- 试验地点
- 2
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
A phase II clinical trial is utilized to examine whether BMS-986253 (25 subjects) or Cabiralizumab (25 subjects) when combined with Nivolumab offers improved radiographic objective response rates (ORR) over Nivolumab monotherapy (25 subjects) in advanced HCC patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have histologically confirmed evidence of HCC, Childs-Pugh score of ≤
- •a. Participants must be willing to provide specimen from fresh, pre- and on-treatment tumor core biopsies for histologic diagnosis and translational studies.
- •Radiographically measurable disease by RECIST1.1 in at least one site.
- •Deemed to not be a candidate for resection or other local-regional therapy.
- •Must not be receiving treatment with other investigational agents and must not have received any other systemic therapy prior to registration.
- •a. Prior radioembolization, local ablative therapies (radiofrequency, microwave or cryoablation), radiation (external beam or stereotactic), or hepatic resection permitted if completed ≥ 4 weeks prior to study enrollment and if patient has recovered with ≤ grade 1 toxicity and if untreated measurable disease is present.
- •Be willing and able to provide written informed consent/assent for the trial.
- •Participants must be ≥ 18 years
- •Have a Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •If hepatitis B is present, participants must be on anti-viral HBV therapy.
- •All women of childbearing potential (not surgically sterilized and between menarche and 1 year post menopause) must have a blood test to rule out pregnancy within 24 hours prior to start of study treatment
- •All women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study treatment (s) and for 5 months following discontinuation of study treatment.
- •Males who are sexually active with women of childbearing potential must agree to follow instructions for method (s) of contraception for the duration of treatment with study treatment and for 7 months following discontinuation of study treatment. Additionally, male participants must not donate sperm during this period.
- •Demonstrate adequate organ function as defined by the following required lab and acceptable range criteria:
- •Adequate bone marrow function:
- •Absolute neutrophil count > 1000/mcL Platelet count > 50,000/mcL Hemoglobin > 8.5 g/dL
- •Adequate hepatic function:
- •Total bilirubin < 2 mg/dL or < 1.5 times upper limit of normal (ULN) AST and ALT < 5 times ULN INR < 1.5 times ULN Albumin > 2.8 g/dL
- •Adequate renal function:
- •Creatinine < 2.0 mg/Dl
排除标准
- •Women who are pregnant or breastfeeding.
- •Presence of other malignancies. Participants with active second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ. NOTE: Patients with history of malignancy are not considered to have a "currently active" malignancy if they have completed therapy and are now considered by their physician to be at less than 30% risk for relapse.
- •Have active or history of Tuberculosis
- •Participants with known HIV positive status
- •Participants with known CNS metastases
- •Uncontrolled ascites
- •Uncontrolled encephalopathy
- •Uncontrolled gastro-esophageal varicesPrior organ allograft or allogeneic bone marrow transplantation
- •Participants with active, known, or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, euthyroid participants with a history of Grave's disease (participants with suspected autoimmune thyroid disorders must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating immunoglobulin prior to first dose of study treatment), psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- •Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration except for adrenal replacement steroid doses > 10 mg daily prednisone equivalent in the absence of active autoimmune disease. Note: Treatment with a short course of steroids (< 5 days) up to 7 days prior to initiating study treatment is permitted.
- •Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity.
- •Uncontrolled or significant cardiovascular disease including, but not limited to, any of the following:
- •Myocardial infarction or stroke/transient ischemic attack within the past 6 months
- •Uncontrolled angina within the past 3 months
- •Any history of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
- •History of other clinically significant heart disease (eg, cardiomyopathy, congestive heart failure with New York Heart Association functional classification III to IV, pericarditis, significant pericardial effusion, or myocarditis)
- •Cardiovascular disease-related requirement for daily supplemental oxygen therapy.
- •Participants with ongoing or active, uncontrolled infections (afebrile for ≥ 48 hours off antibiotics). If hepatitis B is present, must be on anti-viral HBV therapy.
- •Must not have a psychiatric illness, other significant medical illness, or social situation which, in the investigator's opinion, would limit compliance or ability to comply with study requirements.
- •Any major surgery within 4 weeks of study treatment. Participants must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before
- •Any uncontrolled inflammatory disease including Crohn's disease and ulcerative colitis
- •Treatment with botanical preparations (eg, herbal supplements, including potential drugs of abuse, or traditional Chinese medicines) intended for general health support or to treat the disease under study within 2 weeks prior to randomization/treatment.
- •Concomitant use of statins while on study.
- •Current or history of clinically significant muscle disorders (eg, myositis), recent unresolved muscle injury, or any condition known to elevate serum CK levels.
- •Known history of sensitivity to infusions containing Tween 20 (polysorbate 20) and Tween 80 (polysorbate 80).
- •Participants who have received a live / attenuated vaccine within 30 days of first treatment.
- •Concomitant use of any live / attenuated vaccine during treatment and until 100 days following last dose.
研究组 & 干预措施
Nivolumab Monotherapy
Active Comparator
干预措施: Nivolumab 240 mg IV every 2 weeks (Drug)
Nivolumab/BMS-986253 combination
Experimental
干预措施: Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks (Drug)
Nivolumab/BMS-986253 combination
Experimental
干预措施: Nivolumab 240 mg IV every 2 weeks (Drug)
Nivolumab/Cabiralizumab combination
Experimental
干预措施: Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks (Drug)
Nivolumab/Cabiralizumab combination
Experimental
干预措施: Nivolumab 240 mg IV every 2 weeks (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: Every 8 weeks for 1 year and every 3 months thereafter (assessed up to 5 years)
ORR is measured as the percentage of people in a study or treatment group who have a partial response or complete response to the treatment. ORR will be determined based upon RECIST v. 1.1 criteria. Per RECIST v. 1.1 criteria, a Complete Response (CR) is the disappearance of all target lesions, and a Partial Response (PR) is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesions, compared to the baseline.
次要结局
- Progression Free Survival (PFS)(From date of treatment until the date of first documented progression (assessed up to 5 years))
- Overall Survival (OS)(From date of treatment until the date of death from any cause (assessed up to 5 years))
- Time to Response (TTR)(From treatment initiation until first sign of response (up to 5 years))
- Disease Control Rate (DOR)(Through study completion (assessed up to 5 years))
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
2 期
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and NeckLipOral Cavity Squamous Cell CarcinomaPharynxLarynxSquamous Cell CarcinomaNCT03854032Thomas Jefferson University45
已完成
2 期
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerMetastatic Lung Non-Squamous Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Non-Small Cell Cancer AJCC v7NCT03468985National Cancer Institute (NCI)3
进行中（未招募）
2 期
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryVulvar MelanomaMucosal MelanomaNCT05111574National Cancer Institute (NCI)101
招募中
2 期
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerMetastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal CarcinomaStage IV Nasopharyngeal Carcinoma AJCC v8NCT06029270National Cancer Institute (NCI)156
已完成
2 期
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract CancerBiliary Tract NeoplasmsNCT03101566University of Michigan Rogel Cancer Center75